Royalty Pharma
Royalty Pharma, a leading entity in the Pharmaceutical Preparation Manufacturing industry, is headquartered in the United States. Founded in 1996, the company has established itself as a prominent player in the biopharmaceutical sector, focusing on acquiring and managing revenue-generating pharmaceutical royalties. With a robust portfolio that includes innovative therapies across various therapeutic areas, Royalty Pharma distinguishes itself through its unique business model that supports drug development while providing financial returns to investors.
The company operates primarily in North America and Europe, leveraging its extensive network to enhance access to cutting-edge treatments. Notable achievements include strategic partnerships with major pharmaceutical companies, positioning Royalty Pharma as a key contributor to the advancement of life-saving medications. With a commitment to innovation and patient access, Royalty Pharma continues to shape the future of healthcare.
-12 vs industry average
Royalty Pharma’s score of 26 is lower than 41% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Royalty Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Royalty Pharma's reported carbon emissions
Royalty Pharma, a US-based pharmaceutical preparation manufacturer, has reported Scope 3 emissions related to its investments. For 2024, these emissions were approximately 23.3 million kg CO2e. This figure decreased from about 32.0 million kg CO2e in 2023 and was also lower than the approximately 19.6 million kg CO2e recorded in 2022 and about 18.4 million kg CO2e in 2021. Royalty Pharma's reporting for these years indicates a focus on Scope 3 Category 15: GHG Emissions from Investments. The company's current disclosures do not include Scope 1 or Scope 2 emissions data, nor do they specify any overarching reduction targets or commitments to initiatives like the Science Based Targets initiative (SBTi) or the Climate Pledge.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Royalty Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Royalty Pharma yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project